Clinical trials: Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
Pneumonia, Bloodstream Infection
Clinical Outcomes in Patients With Infection by Resistant Microorganism
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and…
- Conditions
- Pneumonia, Bloodstream Infection, Urinary Tract Infections, Skin Infection
- Trial name
- NCT05880069
- Testing
- Pathogen resistant phenotype
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Universitario Virgen Macarena
Carbapenem-Resistant Enterobacteriaceae Infection, Pneumonia - Bacterial
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
Study Design: A randomized, open-label, parallel-group clinical trial comparing the efficacy and safety of jet nebulization versus vibrating mesh nebulization of sulfate polymyxin B in mechanically ventilated patients with…
- Trial name
- NCT07086391
- Testing
- Polymyxin B Sulfate 25mg Jet Nebulization / Vibrating Mesh Nebulization
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Medical University Union Hospital
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Carbapenem Resistant Bacteria Infection
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
Among antibiotic-resistant organisms, the Gram-negative bacteria are now the most important challenge because of the rapid worldwide spread of mechanisms conferring resistance to multiple drugs.
- Trial name
- EURECA (NCT02709408)
- Where
- 50 sites in Albania, Bulgaria and 9 more
- Volunteers
- 2,515 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Diarrhea, Shigella
Multidrug Resistant Shigella Infection in Bangladesh
The purpose of this project is to systematically collect clinical and nutritional outcomes information on patients treated for Shigella infection so that physicians and clinical laboratories can better define which Shigella…
- Trial name
- NCT03778125
- Where
- Bangladesh
- Volunteers
- 2,000 people
- Sponsor
- University of Virginia
Enterobacteriaceae Infections, Community-Acquired Infections
Community-associated Highly-Resistant Enterobacterales
This is a prospective multi-center study. Bacterial isolates from hospitalized patients with CA-HRE will be compared to those from hospitalized patients with healthcare-associated HRE (HA-HRE).
- Conditions
- Enterobacteriaceae Infections, Community-Acquired Infections, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- COCARE (NCT03924934)
- Where
- United States
- Volunteers
- 2,172 people
- Sponsor
- University of North Carolina, Chapel Hill
Critically Ill, Enterobacteriaceae Infections
Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit
There is a lack of data whether colonization and infection with Enterobacteriaceae of the third group (EB3) affect the outcomes for ICU patients.
- Conditions
- Critically Ill, Enterobacteriaceae Infections, Antibiotic Resistant Infection
- Trial name
- EB3REA (NCT04528043)
- Where
- France
- Volunteers
- 179 people
- Sponsor
- Central Hospital, Nancy, France
Infection Due to ESBL Escherichia Coli
Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli
Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the…
- Trial name
- FOREST (NCT02142751)
- Testing
- Fosfomycin sodium intravenous, Meropenem intravenous, Ceftriaxone intravenous
- Where
- 22 sites in Spain
- Volunteers
- 161 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Carbapenemase-Producing Enterobacterales (CPE) Colonization
Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary Hospital
Purpose: Carbapenemase-producing Enterobacterales (CPE) are a growing cause of healthcare-associated infections, linked to high morbidity, mortality, and cost.
- Trial name
- NCT07397416
- Testing
- Rapid PCR-based algorithm for CPE detection
- Volunteers
- 800 people
- Sponsor
- Hospital Italiano de Buenos Aires
Healthcare-Associated Infections (HAIs), Carbapenem-Resistant Enterobacteriaceae Colonization
Correlation Between Carbapenemase-Producing Enterobacterales Load, Environmental Contamination, and Transmission in Critical Care Units
Carbapenemase-producing Enterobacterales (CPE) are multidrug-resistant bacteria that can colonize the gastrointestinal tract of hospitalized patients and spread within intensive care units (ICUs).
- Conditions
- Healthcare-Associated Infections (HAIs), Carbapenem-Resistant Enterobacteriaceae Colonization, Antimicrobial Resistance (AMR)
- Trial name
- CPE-Load ICU S (NCT07685132)
- Where
- Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires
Patients at High Risk of Antibacterial Treatment Upon Admission
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens
Extended-spectrum beta-lactamase producing Enterobacteriaceae (EPE), vancomycin-resistant enterococci (VRE) and Clostridium difficile have become a major threat to hospitalised patients worldwide.
- Trial name
- PILGRIM (NCT03765528)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital of Cologne
Hemato-oncologic Patients, Colonization
Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae
The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to…
- Conditions
- Hemato-oncologic Patients, Colonization, Neutropenia, Enterobacteria Non Susceptible to Carbapenem Carrier
- Trial name
- SCREEN-IN (NCT07396571)
- Where
- 15 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Carbapenem-Resistant Enterobacteriaceae Infection
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
Carbapenem-Resistant Enterobacteriaceae (CRE) infections are a growing national and international challenge in healthcare settings.
- Trial name
- AVI-ICU (NCT05258851)
- Testing
- Ceftazidime-avibactam, Colistin
- Where
- Saudi Arabia
- Volunteers
- 29 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Urinary Tract Infections
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the…
- Trial name
- ELIMINATE (NCT05488340)
- Testing
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose
- Where
- 17 sites in United States
- Volunteers
- 318 people
- Sponsor
- Locus Biosciences
Trauma, Resistant Infection
Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections.
- Conditions
- Trauma, Resistant Infection, Critical Illness
- Trial name
- MUSEUM (NCT03159078)
- Testing
- Polymyxin B
- Where
- Puerto Rico
- Volunteers
- 40 people
- Sponsor
- University of Puerto Rico
Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.
- Conditions
- Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection, Sepsis, Septic Shock
- Trial name
- NCT04516395
- Testing
- Combined antibiotic regimens, Standard antibiotic regimens
- Where
- Thailand
- Volunteers
- 102 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Antibiotic Resistant Strain, Microbial Colonization
Fecal Microbiota Transplantation for Eradication of CRE
Antibiotic resistance has emerged world wide and is of major concern. Multi-drug resistant (MDR) bacteria is widely spread and is now a major factor in morbidity and mortality in health-care settings.
- Trial name
- NCT03167398
- Testing
- Fecal Microbiota Transplantation
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Rambam Health Care Campus
CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
This is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF)…
- Conditions
- CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections, Staphylococcus Aureus Infection
- Trial name
- NCT07280598
- Testing
- Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer